Lu Liu

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Signaling Pathway

Regulatory T Cells

Anti Inflammatory

Top Venues

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lu Liu, Yuxi Lei, Zongyao Zheng, Xingang Zhou, Shuzhen Chen, Guandi Zeng, Lei Yu, Peng Wang, Liang Chen
6-Mercaptopurine potently inhibits recruitment of SHP2 by phosphorylated PD-1 to inhibit PD-1 signalling and enhance T cell function. Immunology (2023)